Hospital

Investigators determined the effectiveness of behavioral activation psychotherapy versus antidepressant medication management for inpatients with heart failure and depression.

Defective RNA editing in cells in the pancreas may spur the body to initiate an inflammatory attack against its own cells.

Inadequate levels of zinc, vitamin D, vitamin E, and vitamin B were also associated with risk of diabetes or diabetes-related complications.

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

The immune checkpoint inhibitor increased inflammation within the tumor, which may be linked to better response to nivolumab treatment.

Dual supplementation can reduce bone loss more than supplementation with vitamin D alone.

Two directors of outpatient services at Allegheny Health Network highlight the significance of Meds-to-Beds in promoting medication adherence while improving patient experience.

Providers can consider the patient’s medication history, comorbidities, or migraine type to help choose a first line treatment or refer the patient to specialized care.

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

No established standard of care currently exists after spread to the lymph nodes.

Please take 10 minutes to complete the 2024 Burnout and Mental Health Survey.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

In hospital pharmacies, roughly 2% of pharmacy spend can be overcharge.

Pharmacists can also ensure proper education and selection of therapy before and after discharge.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.

Jennifer Marsh, PharmD, BCCCP, discusses the current standard of care for hepatic encephalopathy, highlighting challenges in treatment, prescription drug coverage, transition of care, and outpatient treatment access.

The candidate has already demonstrated anti-tumor activity in chemotherapy-naïve patients.

Since 2000, as the number of CDIs has surged, morbidity and mortality also have increased.

Migraine headaches are considered a leading cause of disability around the world.

Tune in to this special episode for an exclusive insight into the future of health technology and wearable innovation, including a glimpse into the world of CES 2024.

According to the FDA review, patients with CKD receiving denosumab for osteoporosis who are on dialysis or have CKD-MBD are at the highest risk of severe hypocalcemia.

Tune into this episode as Dae Lee, PharmD, Esq, CPBS , and Harini Bupathi, Esq, attorneys at Frier Levitt, engage in a thought-provoking conversation on the evolving landscape of pharmacy benefit manager (PBM) audit strategies, regulations, and enforcement.

Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.

Older adults without a Part D plan face costs ranging from $180 to $295 per shot.

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

Access to gene therapies can pose challenges for patients.

Protecting this vulnerable patient population requires specially designed strategies.

Hospital pharmacists can play an important role in advocating for, designing, and implementing various policies to optimize care.

The third edition of the Pharmacy Quality Alliance resource guide includes 40 total SDOH services and 8 new services, as well as 10 initiative updates from the previous 2 editions.

The treatment is for patients with KRAS G12C-mutant metastatic NSCLC who have previously received at least 1 systemic therapy and were not treated with a KRAS G12C inhibitor.